Evidence map›Paper›PMID 42840441›Full record

ArticleExperimental and therapeutic medicine2026

Reversible osimertinib-associated heart failure mimicking cancer recurrence in

Hirona Yokoyama, Nobuhito Hara, Rika Sasaki, Yumi Yoshii, Masahide Ota, Shunsuke Okazaki, Hitoshi Nakagawa, Takeshi Kawaguchi, Masatsugu Hamaji, Yuji Nitta and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hirona YokoyamaCenter for Postgraduate Training, Nara Medical University Hospital, Kashihara, Nara 634-8521, Japan.
Nobuhito HaraDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Rika SasakiDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Yumi YoshiiDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Masahide OtaDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Shunsuke OkazakiDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Hitoshi NakagawaDepartment of Cardiovascular Medicine, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Takeshi KawaguchiDepartment of Thoracic and Cardiovascular Surgery, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Masatsugu HamajiDepartment of Thoracic and Cardiovascular Surgery, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Yuji NittaDepartment of Diagnostic Pathology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Maiko TakedaDepartment of Diagnostic Pathology, Nara Medical University, Kashihara, Nara 634-8521, Japan.
Masayuki TakedaDepartment of Cancer Genomics and Medical Oncology, Nara Medical University, Kashihara, Nara 634-8521, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor widely used in patients with

Indexed as

cardiotoxicityEGFR-mutated non-small cell lung cancerheart failureosimertinibpleural effusionpneumonectomy

Identifiers

PMID42840441
PMCPMC13639783

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.